homepage-top-section

Jyseleca is indicated for usage in moderately to severely active UC adult patients, with insufficient, lost response to or were not tolerant to either standard treatment or a

Leveraging Neurimmune’s reverse translational medicine (RTM) technology platform, the alliance will create antibody therapies against new treatment targets in the neurodegenerative disease field. RTM technology platform is a

The latest move follows the receipt of European Commission (EC) approval for the drug in December last year. Cibinqo, the oral small molecule drug, selectively hinders Janus kinase

As part of the collaboration, the companies will use Prellis Biologics’ externalised human immune system (EXIS) which is based on human lymph node organoids (LNO). The human antibody

The latest move follows the identification of various gene signatures that predict a tumour’s possible response to these drug candidates of Lantern. LP-184 is being analysed as a

The laboratory of Steven Rosenberg, chief of surgery at the NCI, discovered these TCRs. NCI is an institute of the National Institutes of Health (NIH). Neogene’s neoantigen TCR

The collaboration will see the base editing programmes to be evaluated leverage Beam’s in vivo delivery technologies. These technologies use messenger RNA (mRNA) and lipid nanoparticles (LNP) to

The partnership aims to develop new drugs with predictable manufacturing and clinical behaviour. Under the deal, Amgen will make an upfront investment of $50m for the first five

The agreement also includes the lead candidate, OV350, which showed promising in-vitro and in-vivo proof of concept in resistant forms of epilepsy. The early-stage compound directly targets and